Disclosures
Horizon sponsored the study, designed the study with input from an investigator steering committee, contributed to data collection, analysis, and interpretation, and to writing, reviewing, and approval of the final version.Medical writing/analysis: Naina Barretto, PhD, and Robert J. Holt, PharmD, MBA, employees of Horizon Therapeutics. Statistical support was provided by Qianhong Fu, MS, an employee of Horizon.The study sponsor, Horizon Therapeutics, had a role in designing the study, collecting data, analysis and interpretation of data, and writing the final report.The authors’ institutions received funds from Horizon to perform the trial on site; additional disclosures as follows:R.S.D.: Consultant for Horizon, Immunovant, ValenzaBio, and Viridian.S.C.: No additional conflicts.S.T.W.: Advisor to Horizon, Consultant for Immunovant and Sling.B.T.F.: Consultant to Horizon.C.L.: Royalties from Wolters Kluwers Health.P.S.S.: Consultant for Gensight, Horizon, and Viridian.R.T.: Consultant for Viridian, Alexion, Valenza. Investigator for Horizon, Viridian, Novartis, Immunovant, Vasaragen. Speaker for Serono journal club.Q.T.N.: No additional conflicts.R.N.M.: Sub-Investigator in the Horizon teprotumumab clinical trials HZNP-TEP-403, HZNP-TEP-402, and Subcutaneous Phase 1b.S.U. is a consultant for Horizon, Viridian, and Valenza Bio.M.N.S.: Within the last 2 years, his institution has received research support from Horizon Therapeutics, Immunovant, ValenzaBio, Sling Therapeutics, and Lassen Therapeutics. He is a consultant for Septerna Inc, Third Rock Ventures LLC, Genentech, ArgenX US Inc, Tourmaline Bio, Ortho Clinical Diagnostics, OSE Immunotherapeutics, and Roivant Sciences.K.H. and M.K. are employees of Horizon and own stock.